Preston Klassen

2011 - Orexigen Therapeutics

In 2011, Preston Klassen earned a total compensation of $2.1M as Head of Global NB32 Program and Senior Vice President, Product Development at Orexigen Therapeutics, a 111% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$259,000
Option Awards$1,440,066
Salary$370,000
Other$72,120
Total$2,141,186

Klassen received $1.4M in option awards, accounting for 67% of the total pay in 2011.

Klassen also received $259K in non-equity incentive plan, $370K in salary and $72.1K in other compensation.

Rankings

In 2011, Preston Klassen's compensation ranked 3,084th out of 10,747 executives tracked by ExecPay. In other words, Klassen earned more than 71.3% of executives.

ClassificationRankingPercentile
All
3,084
out of 10,747
71st
Division
Manufacturing
1,071
out of 3,960
73rd
Major group
Chemicals And Allied Products
214
out of 1,033
79th
Industry group
Drugs
119
out of 781
85th
Industry
Pharmaceutical Preparations
100
out of 571
83rd
Source: SEC filing on April 30, 2014.

Klassen's colleagues

We found five more compensation records of executives who worked with Preston Klassen at Orexigen Therapeutics in 2011.

2011

Michael Narachi

Orexigen Therapeutics

Chief Executive Officer

2011

Heather Turner

Orexigen Therapeutics

General Counsel

2011

Joseph Hagan

Orexigen Therapeutics

Chief Business Officer

2011

Mark Booth

Orexigen Therapeutics

Chief Commercial Officer

2011

Graham Cooper

Orexigen Therapeutics

Chief Financial Officer

News

In-depth

You may also like